{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T21:50:56Z","timestamp":1767649856091,"version":"build-2065373602"},"reference-count":68,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,3,18]],"date-time":"2020-03-18T00:00:00Z","timestamp":1584489600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurolog\u00eda"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.nrl.2020.02.006","type":"journal-article","created":{"date-parts":[[2020,6,17]],"date-time":"2020-06-17T02:15:48Z","timestamp":1592360148000},"page":"50-60","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Recomendaciones para la vacunaci\u00f3n en pacientes con esclerosis m\u00faltiple candidatos a terapias inmunosupresoras: documento de consenso espa\u00f1ol"],"prefix":"10.1016","volume":"36","author":[{"given":"S.","family":"Otero-Romero","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Rodr\u00edguez-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Vilella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.R.","family":"Ara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Brieva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Calles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Carmona","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Casanova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Costa-Frossard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Eichau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.A.","family":"Garc\u00eda-Merino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Garcia-Vidal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Gonz\u00e1lez-Platas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Llaneza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Mart\u00ednez-Gin\u00e9s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.E.","family":"Meca-Lallana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.M.","family":"Prieto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Rodr\u00edguez-Antig\u00fcedad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Tintor\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Blanco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Moral","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.nrl.2020.02.006_bib0345","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1016\/S0140-6736(18)30481-1","article-title":"Multiple sclerosis","volume":"391","author":"Thompson","year":"2018","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.nrl.2020.02.006_bib0350","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/nrneurol.2016.188","article-title":"Treatment decisions in multiple sclerosis - insights from real-world observational studies","volume":"13","author":"Trojano","year":"2017","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.nrl.2020.02.006_bib0355","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.2147\/DDDT.S137572","article-title":"Comparison of efficacy and safety of oral agents for the treatment of relapsing-remitting multiple sclerosis","volume":"11","author":"Guarnera","year":"2017","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.nrl.2020.02.006_bib0360","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s40263-017-0414-3","article-title":"Monoclonal antibodies for relapsing multiple sclerosis: A review of recently marketed and late-stage agents","volume":"31","author":"Blinkenberg","year":"2017","journal-title":"CNS Drugs"},{"key":"10.1016\/j.nrl.2020.02.006_bib0365","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s40264-018-0782-8","article-title":"Managing risks with immune therapies in multiple sclerosis","volume":"42","author":"Forster","year":"2019","journal-title":"Drug Saf"},{"key":"10.1016\/j.nrl.2020.02.006_bib0370","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/S0140-6736(85)92801-6","article-title":"Clinical viral infections and multiple sclerosis","volume":"1","author":"Sibley","year":"1985","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.nrl.2020.02.006_bib0375","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1002\/ana.410360709","article-title":"Influence of infection on exacerbations of multiple sclerosis","volume":"36 Suppl","author":"Panitch","year":"1994","journal-title":"Ann Neurol"},{"key":"10.1016\/j.nrl.2020.02.006_bib0380","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1136\/jnnp.64.6.736","article-title":"Clinical relapses and disease activity on magnetic resonance imaging associated with viral upper respiratory tract infections in multiple sclerosis","volume":"64","author":"Edwards","year":"1998","journal-title":"J Neurol, Neurosurg Psychiatry"},{"key":"10.1016\/j.nrl.2020.02.006_bib0385","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0022-510X(98)00139-7","article-title":"Effects of influenza vaccination and influenza illness on exacerbations in multiple sclerosis","volume":"159","author":"De Keyser","year":"1998","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.nrl.2020.02.006_bib0390","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1111\/ene.12130","article-title":"Hospital admission due to infections in multiple sclerosis patients","volume":"20","author":"Montgomery","year":"2013","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.nrl.2020.02.006_bib0395","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1212\/WNL.0000000000008157","article-title":"Practice guideline update summary: Vaccine-preventable infections and immunization in multiple sclerosis: Report of the guideline development dissemination, and implementation subcommittee of the American Academy of Neurology","volume":"93","author":"Farez","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.nrl.2020.02.006_bib0400","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.msard.2019.04.004","article-title":"Immunization and multiple sclerosis: Recommendations from the French multiple sclerosis society","volume":"31","author":"Lebrun","year":"2019","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.nrl.2020.02.006_bib0405","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/nrneurol.2012.8","article-title":"Vaccination against infection in patients with multiple sclerosis","volume":"8","author":"Loebermann","year":"2012","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.nrl.2020.02.006_bib0410","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1212\/WNL.59.12.1837","article-title":"Immunization and MS: A summary of published evidence and recommendations","volume":"59","author":"Rutschmann","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.nrl.2020.02.006_bib0415","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1093\/rheumatology\/keq183","article-title":"Vaccinations in patients with immune-mediated inflammatory diseases","volume":"49","author":"Rahier","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.nrl.2020.02.006_bib0420","first-page":"317","article-title":"Vaccinations in adults with rheumatoid arthritis in an era of new disease-modifying anti-rheumatic drugs","volume":"36","author":"Meroni","year":"2018","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.nrl.2020.02.006_bib0425","first-page":"247","article-title":"Improving immunization strategies in patients with inflammatory bowel disease","volume":"32","author":"Farshidpour","year":"2019","journal-title":"Ann Gastroenterol"},{"key":"10.1016\/j.nrl.2020.02.006_bib0430","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJM200102013440501","article-title":"Vaccinations and the risk of relapse in multiple sclerosis","volume":"344","author":"Confavreux","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nrl.2020.02.006_bib0435","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1007\/s00415-011-5984-2","article-title":"Immunizations and risk of multiple sclerosis: Systematic review and meta-analysis","volume":"258","author":"Farez","year":"2011","journal-title":"J Neurol"},{"issue":"Suppl 201","key":"10.1016\/j.nrl.2020.02.006_bib0440","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/ane.12837","article-title":"Vaccines and multiple sclerosis","volume":"136","author":"Frederiksen","year":"2017","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.nrl.2020.02.006_bib0445","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.3389\/fimmu.2019.01883","article-title":"Vaccination in multiple sclerosis: Friend or foe?","volume":"10","author":"Zrzavy","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.nrl.2020.02.006_bib0450","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1007\/s00115-019-00806-x","article-title":"[Indications for varicella zoster and herpes zoster vaccination in multiple sclerosis: Current situation]","volume":"90","author":"Winkelmann","year":"2019","journal-title":"Der Nervenarzt"},{"key":"10.1016\/j.nrl.2020.02.006_bib0455","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1001\/archneurol.2011.131","article-title":"Yellow fever vaccination and increased relapse rate in travelers with multiple sclerosis","volume":"68","author":"Farez","year":"2011","journal-title":"Arch Neurol"},{"key":"10.1016\/j.nrl.2020.02.006_bib0460","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.msard.2013.03.002","article-title":"Varicella vaccination after fingolimod: A case report","volume":"2","author":"Berger","year":"2013","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.nrl.2020.02.006_bib0465","doi-asserted-by":"crossref","first-page":"A1","DOI":"10.1016\/j.msard.2018.10.017","article-title":"Vaccines and disease-modifying treatments","volume":"26","author":"Waubant","year":"2018","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.nrl.2020.02.006_bib0470","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1080\/08916934.2017.1373766","article-title":"Effects of immunomodulators on the response induced by vaccines against autoimmune diseases","volume":"50","author":"Marciani","year":"2017","journal-title":"Autoimmunity"},{"key":"10.1016\/j.nrl.2020.02.006_bib0475","doi-asserted-by":"crossref","first-page":"e409","DOI":"10.1212\/NXI.0000000000000409","article-title":"Immune response to vaccines is maintained in patients treated with dimethyl fumarate","volume":"5","author":"von Hehn","year":"2018","journal-title":"Neurology(R) neuroimmunology & neuroinflammation"},{"key":"10.1016\/j.nrl.2020.02.006_bib0480","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/cns.13034","article-title":"Immunogenicity and predictors of response to a single dose trivalent seasonal influenza vaccine in multiple sclerosis patients receiving disease-modifying therapies","volume":"25","author":"Metze","year":"2019","journal-title":"CNS Neurosci Ther"},{"key":"10.1016\/j.nrl.2020.02.006_bib0485","doi-asserted-by":"crossref","first-page":"e196","DOI":"10.1212\/NXI.0000000000000196","article-title":"Patients with MS under daclizumab therapy mount normal immune responses to influenza vaccination","volume":"3","author":"Lin","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.nrl.2020.02.006_bib0490","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jns.2014.03.035","article-title":"Natalizumab treatment shows no clinically meaningful effects on immunization responses in patients with relapsing-remitting multiple sclerosis","volume":"341","author":"Kaufman","year":"2014","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.nrl.2020.02.006_bib0495","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1212\/WNL.0000000000001302","article-title":"Randomized trial of vaccination in fingolimod-treated patients with multiple sclerosis","volume":"84","author":"Kappos","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.nrl.2020.02.006_bib0500","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s11908-017-0562-0","article-title":"Infectious complications of novel multiple sclerosis therapies","volume":"19","author":"Levin","year":"2017","journal-title":"Current Infect Dis Rep"},{"key":"10.1016\/j.nrl.2020.02.006_bib0505","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1212\/WNL.0000000000001319","article-title":"Multiple sclerosis, immunomodulation, and immunizations: Balancing the benefits","volume":"84","author":"Goldman","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.nrl.2020.02.006_bib0510","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofy174","article-title":"Infectious complications of multiple sclerosis therapies: Implications for screening prophylaxis, and management","volume":"5","author":"Epstein","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.nrl.2020.02.006_bib0515","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.vaccine.2017.01.048","volume":"35","author":"Croce","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.nrl.2020.02.006_bib0520","unstructured":"Ponencia del Programa y Registro de Vacunaciones. Vacunaci\u00f3n en poblaci\u00f3n adulta. Comisi\u00f3n de Salud P\u00fablica del Consejo Interterritorial del Sistema Nacional de Salud. En: Ministerio de Sanidad CyBS. Disponible en: http:\/\/www.mscbs.gob.es2018"},{"key":"10.1016\/j.nrl.2020.02.006_bib0685","first-page":"2","volume":"10","author":"Salleras","year":"2014","journal-title":"Medicina Preventiva."},{"key":"10.1016\/j.nrl.2020.02.006_bib0530","first-page":"142","article-title":"[Consensus document on pneumococcal vaccination in adults at risk by age and underlying clinical conditions 2017 Update]","volume":"30","author":"Gonzalez-Romo","year":"2017","journal-title":"Rev Esp Quimioter"},{"key":"10.1016\/j.nrl.2020.02.006_bib0535","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2019.24.7.1700857","article-title":"Multidisciplinary, evidence-based consensus guidelines for human papillomavirus (HPV) vaccination in high-risk populations, Spain, 2016 Euro surveillance","volume":"24","author":"Martinez-Gomez","year":"2019","journal-title":"Eur Surveill"},{"key":"10.1016\/j.nrl.2020.02.006_bib0540","doi-asserted-by":"crossref","unstructured":"Salleras L, Bayas J, Campins M, Castrodeza J, Dom\u00ednguez A, Dom\u00ednguez V. Calendario de vacunaciones sistem\u00e1ticas del adolescente y adulto recomendado por la Sociedad Espa\u00f1ola de Medicina Preventiva, Salud P\u00fablica e Higiene (actualizaci\u00f3n del a\u00f1o 2014).","DOI":"10.1016\/S1576-9887(14)70089-5"},{"key":"10.1016\/j.nrl.2020.02.006_bib0545","doi-asserted-by":"crossref","first-page":"115","DOI":"10.15585\/mmwr.mm6805a5","article-title":"Advisory Committee on immunization practices recommended immunization schedule for adults aged 19 years or older-United States, 2019","volume":"68","author":"Kim","year":"2019","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.nrl.2020.02.006_bib0550","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1093\/cid\/cit816","article-title":"2013 IDSA clinical practice guideline for vaccination of the immunocompromised host","volume":"58","author":"Rubin","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.nrl.2020.02.006_bib0555","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.rdc.2016.09.003","article-title":"Vaccines and disease-modifying antirheumatic drugs: Practical implications for the rheumatologist","volume":"43","author":"Friedman","year":"2017","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.nrl.2020.02.006_bib0560","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.jinf.2017.02.009","article-title":"Diagnostic and vaccine strategies to prevent infections in patients with inflammatory bowel disease","volume":"74","author":"Mazzola","year":"2017","journal-title":"J Infect"},{"key":"10.1016\/j.nrl.2020.02.006_bib0565","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.3748\/wjg.v19.i9.1354","article-title":"Vaccines and recommendations for their use in inflammatory bowel disease","volume":"19","author":"Sanchez-Tembleque","year":"2013","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.nrl.2020.02.006_bib0570","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1136\/ard.2010.137216","article-title":"EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases","volume":"70","author":"Van Assen","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.nrl.2020.02.006_bib0575","doi-asserted-by":"crossref","DOI":"10.3310\/hta2160","article-title":"Qualitative research methods in health technology assessment: A review of the literature","volume":"2","author":"Murphy","year":"1998","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.nrl.2020.02.006_bib0580","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6702a1","article-title":"Prevention of Pertussis tetanus, and diphtheria with vaccines in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"67","author":"Liang","year":"2018","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.nrl.2020.02.006_bib0690","first-page":"816","article-title":"Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"61","year":"2012","journal-title":"MMWR Morb Mortal Wkly Rep."},{"key":"10.1016\/j.nrl.2020.02.006_bib0590","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1212\/WNL.0000000000004216","article-title":"Mortality trends for multiple sclerosis patients in Sweden from 1968 to 2012","volume":"89","author":"Burkill","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.nrl.2020.02.006_bib0595","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1007\/s11910-017-0800-8","article-title":"Infections in patients receiving multiple sclerosis disease-modifying therapies","volume":"17","author":"Grebenciucova","year":"2017","journal-title":"Curr Neurol Neurosci Rep"},{"key":"10.1016\/j.nrl.2020.02.006_bib0600","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1186\/s13075-014-0506-0","article-title":"Effects of biological and non-biological immunomodulatory therapies on the immunogenicity of vaccines in patients with rheumatic diseases","volume":"16","author":"McMahan","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.nrl.2020.02.006_bib0605","unstructured":"Ponencia de programa y registro de vacunaciones. Vacunaci\u00f3n en grupos de riesgo de todas las edades y en determinadas situaciones. Comisi\u00f3n de Salud P\u00fablica del Consejo Interterritorial del Sistema Nacional de Salud. Disponible en: http:\/\/www.mscbs.gob.es2018"},{"key":"10.1016\/j.nrl.2020.02.006_bib0610","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S0140-6736(12)61769-3","article-title":"Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial","volume":"380","author":"Cohen","year":"2012","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.nrl.2020.02.006_bib0615","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nrl.2020.02.006_bib0620","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6703a1","article-title":"Prevention and control of seasonal influenza with vaccines: Recommendations of the Advisory Committee on Immunization Practices-United States, 2018-19 Influenza Season","volume":"67","author":"Grohskopf","year":"2018","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.nrl.2020.02.006_bib0625","unstructured":"Vacunaciones PdPyRd. Recomendaciones de vacunaci\u00f3n frente a hepatitis A en grupos de riesgo. Comisi\u00f3n de Salud P\u00fablica del Consejo Interterritorial del Sistema Nacional de Salud. Disponible en: http:\/\/www.mscbs.gob.es2017"},{"key":"10.1016\/j.nrl.2020.02.006_bib0630","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1111\/ajt.14683","article-title":"Recommendations of the Advisory Committee on Immunization Practices for use of herpes zoster vaccines","volume":"18","author":"Dooling","year":"2018","journal-title":"Am J Transplant"},{"key":"10.1016\/j.nrl.2020.02.006_bib0635","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1080\/21645515.2017.1264797","article-title":"Recommended vaccinations for asplenic and hyposplenic adult patients","volume":"13","author":"Bonanni","year":"2017","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.nrl.2020.02.006_bib0640","doi-asserted-by":"crossref","DOI":"10.1177\/1756286419836571","article-title":"Risks and risk management in modern multiple sclerosis immunotherapeutic treatment","volume":"12","author":"Klotz","year":"2019","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.nrl.2020.02.006_bib0645","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/BF01062461","article-title":"Pharmacoimmunodynamics of methylprednisolone: Trafficking of helper T lymphocytes","volume":"20","author":"Fisher","year":"1992","journal-title":"J Pharmacokinet Biopharm"},{"key":"10.1016\/j.nrl.2020.02.006_bib0650","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.vaccine.2014.06.068","article-title":"Efficacy of vaccination against influenza in patients with multiple sclerosis: The role of concomitant therapies","volume":"32","author":"Pellegrino","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.nrl.2020.02.006_bib0655","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jbspin.2015.08.008","article-title":"Vaccinations in adults with chronic inflammatory joint disease: Immunization schedule and recommendations for patients taking synthetic or biological disease-modifying antirheumatic drugs","volume":"83","author":"Morel","year":"2016","journal-title":"J Bone Spine"},{"key":"10.1016\/j.nrl.2020.02.006_bib0660","first-page":"217","article-title":"Travel advice for the immunocompromised traveler: prophylaxis, vaccination, and other preventive measures","volume":"11","author":"Patel","year":"2015","journal-title":"Ther Clin Risk Manag"},{"issue":"10 Suppl 6","key":"10.1016\/j.nrl.2020.02.006_bib0665","first-page":"S23","article-title":"Vaccinations recommended during pregnancy and breastfeeding","volume":"111","author":"Hubka","year":"2011","journal-title":"J Am Osteopath Assoc"},{"key":"10.1016\/j.nrl.2020.02.006_bib0670","doi-asserted-by":"crossref","first-page":"104","DOI":"10.3389\/fonc.2019.00104","article-title":"Progress in EBV vaccines","volume":"9","author":"Van Zyl","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.nrl.2020.02.006_bib0675","first-page":"95","article-title":"Varicella-zoster virus infection: Natural history, clinical manifestations, immunity and current and future vaccination strategies","volume":"41","author":"Freer","year":"2018","journal-title":"New Microbiol"},{"key":"10.1016\/j.nrl.2020.02.006_bib0680","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1080\/21645515.2018.1451810","article-title":"Progress toward the global control of Neisseria meningitidis: 21st century vaccines, current guidelines, and challenges for future vaccine development","volume":"14","author":"Dretler","year":"2018","journal-title":"Hum Vaccin Immunother"}],"container-title":["Neurolog\u00eda"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213485320300451?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213485320300451?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T13:12:37Z","timestamp":1759324357000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0213485320300451"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":68,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["S0213485320300451"],"URL":"https:\/\/doi.org\/10.1016\/j.nrl.2020.02.006","relation":{},"ISSN":["0213-4853"],"issn-type":[{"type":"print","value":"0213-4853"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recomendaciones para la vacunaci\u00f3n en pacientes con esclerosis m\u00faltiple candidatos a terapias inmunosupresoras: documento de consenso espa\u00f1ol","name":"articletitle","label":"Article Title"},{"value":"Neurolog\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nrl.2020.02.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Sociedad Espa\u00f1ola de Neurolog\u00eda. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}